Johnson & Johnson must pay $572m for its part in US opioid epidemic, judge rules
Penalty fell much below what state of Oklahoma sought, leading to spike in after-hours trading for drugmaker
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Pharmaceutical company Johnson & Johnson has been ordered to pay more than half a billion dollars for its part in fuelling the opioid epidemic, which has led to tens of thousands of deaths a year in the United States.
The order to pay $572m (£468m) comes from an Oklahoma judge, in a case that has been closely watched to see if a court would hold the drugmaker responsible for its contribution to the American crisis. It marks the first major blow for the pharmaceutical industry on the issue, as it faces numerous lawsuits across the country from states and municipalities torn by the impact of the potent drugs.
In his ruling, Judge Thad Balkman found that the state of Oklahoma had met its burden of proof in accusing Johnson & Johnson, through its subsidiary Janssen, of creating a public nuisance by spreading misinformation about the painkillers.
The companies, Oklahoma attorney general Mike Hunter alleged in the state’s lawsuit, had used deceptive and aggressive marketing campaigns to push the addictive drugs and their use across the country.
“Specifically, defendants caused an opioid crisis that’s evidenced by increased rates of addiction, overdose deaths and neonatal abstinence syndrome,” Mr Balkman said. He described the opioid crisis as an “imminent danger and menace”.
Johnson & Johnson has signalled that it plans on appealing the decision, which is much less than the penalties originally sought by the state of Oklahoma. That difference sent the company’s stock up by more than 5 per cent in post-market trading, following the verdict.
Other pharmaceutical companies such as Mallinckrodt, Teva Pharmaceutical, and Endo International also saw their stock prices rise in after-hours trading following the news.
The lawsuit originally began with three defendants, including Johnson & Johnson, Teva Pharmaceutical, and Purdue Pharma, the privately held maker of Oxycontin that has been widely blamed for the crisis. The latter two companies reached settlements with the state before the seven-week trial began.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments